H1B Salary Data

Home › Occupations › Regulatory Affairs Managers › Boston, MA

Regulatory Affairs Managers in Boston, MA: H-1B salaries

44 labor condition applications for this occupation with a work site in Boston, MA. Median offered base salary $180,300; middle half $147,494–$223,718.

Applications (LCAs)44
Median offered salary$180,300
Middle half of salaries$147,494–$223,718
10th–90th percentile$94,082–$292,345

By wage level

Wage levelMedian salary
Level I (entry)$91,083
Level II (qualified)$155,765
Level III (experienced)$190,325
Level IV (fully competent)$222,435

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Employers

EmployerLCAsMedian salary
Vertex Pharmaceuticals Incorporated5$195,500
argenx US, Inc.4$182,825
General Hospital Corporation3$91,083
AstraZeneca Pharmaceuticals LP3$257,088
CRISPR Therapeutics, Inc.3$235,000
OW North America LLC2$127,471
Servier Bio-Innovation LLC2$260,580
McKinsey & Company, Inc. United States2$370,450
Rhythm Pharmaceuticals Inc.2$165,000
Biogen Inc.1$89,960
Pear Therapeutics, Inc.1$136,000
Sonos, Inc.1$111,904
eClinicalWorks LLC1$180,300
Beth Israel Deaconess Medical Center, Inc.1$84,897
Elektrofi, Inc.1$180,294
InGenius LLC1$89,960
Inozyme Pharma1$240,000
Wayfair LLC1$169,251
Praxis Precision Medicines, Inc.1$225,000
Orsted North America Inc.1$330,000
PepGen Inc.1$230,000
Copenhagen Offshore Partners Inc.1$180,049
Ultragenyx Pharmaceutical, Inc.1$210,891
Labviva1$162,000
AVEO Pharmaceuticals, Inc.1$160,000
EMD Serono Research and Development Institute, Inc.1$176,000
Alexion Pharmaceuticals, Inc.1$125,260

Job titles

H-1B sponsors in Boston, MA →

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).